ABSTRACT BACKGROUND Sodium glucose co-transporter 2 inhibitors may reduce cardiovascular and heart failure risk in patients
S odium glucose co-transporter 2 (SGLT2) inhibitors are a new class of diabetes drugs that lower blood glucose in patients with type 2 diabetes mellitus (T2DM) through increased urinary excretion of glucose (1) . SGLT2 inhibitors may have other cardiometabolic benefits; they cause natriuresis, a mild osmotic diuresis, and a net caloric loss that contribute to reductions in body weight and blood pressure (BP) (1) . Additionally, increased delivery of sodium to the macula densa helps to restore normal glomerular pressure, which, in turn, results in improved renal function over the longer term (2) . SGLT2 inhibitors have recently been studied in large cardiovascular outcomes trials for evaluating the cardiovascular effects of newer T2DM agents (3).
In the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) study, treatment with empagliflozin resulted in reduction in the risk for major adverse cardiovascular events (3-point MACE: cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction) compared with placebo, driven by a 38% reduction in cardiovascular death; empagliflozin also reduced the risk of hospitalization for heart failure by 35% relative to placebo (4) . These effects were apparent early after initiating treatment with empagliflozin, suggesting that acute changes may be at least partially responsible for the observed outcomes (4) . Hypotheses regarding the mechanism of cardiovascular benefit for SGLT2 inhibition observed in the EMPA-REG OUTCOME study have focused on the multiple effects beyond glucose lowering, such as diuresis and natriuresis, weight loss, BP lowering, metabolic effects on the myocardium, favorable hemodynamic changes, and attenuation of cardiac remodeling (5-12); each may result in improved cardiovascular outcomes (11) .
Biomarkers are useful in prognosis determination
and informing the mechanism of benefit provided by therapeutic agents (13) . N-terminal pro-B-type natriuretic peptide (NT-proBNP) is recommended for the diagnosis and management of heart failure, with potential utility in the prediction of coronary heart disease and stroke outcomes (14) . Similarly, biomarkers of cardiomyocyte injury (e.g., highsensitivity troponin I [hsTnI]) and those involved in cardiovascular stress/tissue fibrosis (e.g., soluble
[s]ST2, galectin-3) may help elucidate prognosis and disease progression, with recent data, in particular, for hsTnI in T2DM (15) .
There are very limited data on the effects of SGLT2 inhibitors on cardiovascular biomarkers (16) (17) (18) . In this study, we sought to assess the longitudinal changes in the concentrations of NT-proBNP, hsTnI, sST2, and galectin-3 in older patients with T2DM randomized to receive canagliflozin or placebo in a 104-week study (19, 20) to gain insights into the mechanisms of the potential beneficial cardiovascular effect of SGLT2 inhibitors.
METHODS
PATIENTS. This post hoc, exploratory analysis was conducted using stored serum samples from a 104-week, randomized, and these patients were included in this analysis.
Among patients included in the biomarker assessments, baseline characteristics were balanced between groups and were generally consistent with the overall study population ( Table 1) ; 77% had a history of hypertension and 30% had a history of microvascular disease (i.e., neuropathy, retinopathy, or nephropathy). The majority of patients (74%) were taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; 25%, 23%, and 34% of patients were on beta-blockers, calcium-channel blockers, and diuretic agents, respectively ( Table 1) .
Of those taking diuretic agents, the majority took thiazides (29.2% in the placebo arm and 28.9% in the canagliflozin arm), whereas loop diuretic agents (4.6% and 3.6%) or mineralocorticoid receptor antagonists (0.5% and 3.1%) were less commonly used.
During the course of the study, no changes in electrocardiographic parameters, such as PR interval, QRS interval, QT/QTc, or RR intervals, were noted between treatment groups (data not shown).
BIOMARKER CHANGES. Table 2 summarizes the observed changes in serum NT-proBNP, hsTnI, sST2, galectin-3, eGFR, and hematocrit at all time points.
From a baseline median of approximately 47 pg/ml, serum NT-proBNP concentrations increased with placebo, but changed only minimally with canagliflozin over the 2-year study period ( Figure 1A ). to À2.5%), À11.9% (95% CI: À18.0% to À5.6%), and À10.0% (95% CI: À17.3% to À2.6%), respectively.
Differences between canagliflozin and placebo were significant at each time point (nominal p < 0.01 for each between-group difference). Considering the correlation between baseline and 104-week concentrations of hsTnI (Online Figure 1B) , a lower slope from baseline to final measurement was observed in those treated with canagliflozin.
Baseline serum sST2 concentrations were approximately 29 ng/ml. In contrast to NT-proBNP and hsTnI, median sST2 levels were unchanged in both the canagliflozin and placebo groups at each time point With the exception of a negative correlation between galectin-3 concentrations and eGFR, there were generally no clinically meaningful correlations between change in biomarkers and change in selected physiological parameters at any time point (Online Table 1 ).
In a sensitivity analysis among patients who had biomarker data at baseline and all 3 time points, changes in cardiovascular biomarkers were consistent with those seen in the primary analysis (Online Figures 2A to 2D ).
DISCUSSION
In this randomized trial of older patients with T2DM
with biomarker profiles consistent with a generally higher risk for cardiovascular events, we found that serum concentrations of NT-proBNP and hsTnI, bio- Januzzi, Jr. et al.
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A U G U S T 8 , 2 0 1 7 : 7 0 4 -1 2 OUTCOME study could be expected from treatment with all SGLT2 inhibitors, our results provide novel data regarding possible cardiovascular benefits from canagliflozin treatment.
Numerous theories have emerged to explain how SGLT2 inhibitors may reduce cardiovascular risk;
however, no consensus exists as to the mechanism of such risk reduction. The early divergence of survival curves seen in the EMPA-REG OUTCOME study suggests an acute effect in particular on heart failure outcomes (4). It has been proposed that sodium and fluid loss, reduction in BP and body weight, attenuation of inflammation and oxidative stress, improvement in arterial stiffness, as well as preservation of renal function may contribute to the observed cardiac benefits (7, 10, 11, 23) . Interest has also focused on metabolic effects in the myocardium, including changes in glucagon handling, mitigation of glucotoxicity, and shift to fatty acid metabolism, as well as attenuation of cardiac remodeling (5-9,11). Treatment with SGLT2 inhibitors has been shown to increase levels of ketone bodies, which may be a more favorable energetic substrate for the heart compared with However, small changes in both biomarkers may be substantially prognostic, and consistency across multiple time points suggests that these changes for NT-proBNP and hsTnI are more likely to be robust.
Lastly, we lack data on other novel biomarkers with prognostic value such as mid-regional proadrenomedullin or growth differentiation factor-15.
Larger studies should confirm our findings, and,
ideally, future outcomes trials should examine links between biomarker changes and long-term cardiovascular disease outcomes.
CONCLUSIONS
Our findings suggest that canagliflozin treatment was associated with attenuation of biomarkers associated with adverse cardiovascular outcomes in this study population of older patients with T2DM. As it is difficult to know for sure whether the benefits seen in the EMPA-REG OUTCOME study related to treatment Januzzi, Jr. et al.
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